s
s
s
Develop highly selective and sensitive PK and ADA assays for trastuzumab (Herceptin) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Trastuzumab and Trastuzumab-ErbB2 Complex.
Specificity Binding Type |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Trastuzumab Inhibitory Type 1 |
HCA166 |
AbD16712 |
Fab-V5Sx21 |
0.2 |
PK bridging ELISA |
|
HCA167 |
AbD16714 |
Fab-V5Sx21 |
2.5 |
PK bridging ELISA |
||
HCA168 |
AbD18018 |
Fab-FH2 |
0.02 |
PK bridging ELISA |
||
HCA169 |
AbD18141 |
Fab-FH2 |
0.2 |
PK bridging ELISA |
||
HCA176 |
AbD16712_hIgG1 |
hIgG1 HRP |
0.4 |
PK bridging ELISA ADA control |
||
HCA177 |
AbD18018_hIgG1 |
hIgG1 HRP |
0.02 |
PK bridging ELISA ADA control |
||
HCA270 |
AbD18018_hIgG4Pro |
hIgG4-Pro3 |
0.02 |
PK bridging ELISA |
||
Trastuzumab-ErbB2 (HER2) Complex Specific |
HCA263 |
AbD25279 |
Fab-A-FH4 |
31 |
PK ELISA antigen capture format |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody, V5- and StrepX-StrepX- tags
2 Monovalent Fab antibody DYKDDDDK- and His-6-tags
3 Human IgG4-Pro isotype has a point mutation S228P to prevent Fd half molecule exchange
4 Bivalent Fab2, bacterial alkaline phosphatase dimerization domain, DYKDDDDK- and His-6-tags
Type 1 anti-trastuzumab antibodies inhibit the binding of the drug trastuzumab to its target, the extracellular domain of the human epidermal growth factor receptor 2, ErbB2 (also known as HER2). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
The Type 3 antibody specifically recognizes the drug-target complex, detecting trastuzumab only when it is bound to ErbB2 (HER2). It is suitable as a detection antibody in a PK antigen capture assay.
Fig. 1. Trastuzumab PK bridging ELISA using antibodies HCA168 and HCA166
Schematic image of PK bridging ELISA. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Trastuzumab PK bridging ELISA using antibodies HCA169 and HCA270, with HRP conjugated anti-hIgG4, MCA2098P (secondary).
Schematic image of PK bridging ELISA (IgG4). Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), detection with anti-idiotypic antibody IgG4 isotype format (blue), and anti-human IgG4 labeled with HRP (gray).
Fig. 3. Trastuzumab PK antigen capture ELISA using antibody HCA263.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug target complex detection antibody, monovalent Fab format (purple), labeled with HRP.
Fig. 4. Trastuzumab ADA bridging ELISA using antibody HCA177.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.